High-level amikacin resistance in Escherichia coli due to phosphorylation and impaired aminoglycoside uptake.
Plasmid pMP1-1 in Escherichia coli L-0 encodes aminoglycoside (AG) 3'-phosphotransferase II [APH(3')-II]. This enzyme modifies and confers high-level resistance to kanamycin. Although amikacin is a substrate for APH(3')-II, strain L-0(pMP1-1) is susceptible to amikacin. Plasmid pMP1-2 is a spontaneous mutant of pMP1-1 which determines increased APH(3')-II activity for amikacin, apparently as a result of an increase in the copy number of the plasmid. From amikacin-susceptible, gentamicin-susceptible transformants and transconjugants that bear the APH(3')-II gene on plasmid pMP1-1 or pMP1-2 or cloned into multicopy plasmid pBR322, we selected spontaneous mutants at concentrations of amikacin or gentamicin that were two to four times higher than the MICs of these antibiotics. In each case, whether they were selected by using amikacin or gentamicin, the mutants exhibited modest (two- to eightfold) increases in the MIC of gentamicin and major (64- to 128-fold) increases in the MIC of amikacin. Using these laboratory strains of E. coli, we examined the effects on AG susceptibility of the interaction of AG-modifying enzyme activity and generalized AG uptake. Increasing the level of activity of an AG phosphotransferase in these strains lowered their susceptibility to AGs which were substrates for which the enzyme had low Kms. However, an increase in AG-modifying activity alone did not result in large increases in the MICs for poor substrates of the enzyme. In strains which lacked AG-modifying enzymes, a decrease in the rate of AG uptake increased the MICs modestly for a broad spectrum of AGs. When a strain bore the phosphotransferase, a decrease in generalized AG uptake could raise the MIC further, not only for low-Km substrates, but even for AG substrates for which the enzyme had high Kms. Thus, increased modifying activity, together with a diminished rate of uptake, could produce even higher MICs for poor AG substrates.
D000583:Amikacin / Q000378:metabolism / Q000494:pharmacology*; D000617:Aminoglycosides / Q000378:metabolism*; D004269:DNA, Bacterial / Q000032:analysis; D004096:Dihydrostreptomycin Sulfate / Q000378:metabolism; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D007612:Kanamycin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D019868:Kanamycin Kinase; D007700:Kinetics; D008564:Membrane Potentials; D009154:Mutation; D010766:Phosphorylation; D010770:Phosphotransferases / Q000378:metabolism*; D011815:R Factors
D000617:Aminoglycosides; D004269:DNA, Bacterial; D007612:Kanamycin; D000583:Amikacin; D010770:Phosphotransferases; D019868:Kanamycin Kinase; D004096:Dihydrostreptomycin Sulfate